Parion Sciences, which is developing a trans-nasal aerosol delivery system and several products for cystic fibrosis, has announced several changes to its executive team. Paul Boucher, previously VP of Finance & Business has been promoted to President; Joe Schachle, previously Head of Global Marketing Operations at Grifols, has been hired as Chief Operating Officer; and former RTI Regulatory Project Leader Anita Woodring has joined the company as Senior Director of Clinical & Regulatory Operations.
The company also said that it will initiate a Phase 1/2 study of its tPAD (transnasal pulmonary aerosol delivery) system for the treatment of CF this year. A Phase 2 study of P-1037, an epithelial sodium channel inhibitor for the treatment of CF licensed from Gilead, is also planned later in 2014.
Parion Board Co-Chairman and Founder Ross Johnson commented, “We are at an important inflection point in our company’s history as we progress our programs in the clinic. We are pleased to recognize Paul’s leadership at Parion and to have him lead the company into our next phase of growth. We are also pleased to have Joe and Anita join our team to provide additional corporate, commercial, and R&D experience.”
Read the Parion press release.
